Panthera supports clinical trials via recruitment and management of patients through the trial process.

Patient recruitment and retention has been a major pain point in trials and the development of novel drugs, and Panthera’s contribution to medical research and the advancement of medical interventions aims to ensure that future generations receive the very best in new treatments.

Its research sites operate across the UK, with clinics in London, Preston, Manchester, and Glasgow with more planned.

Gresham House Ventures provided Series A funding alongside Catapult Ventures.


Investment rationale

The funding will ensure Panthera has the backing to provide pharmaceutical clients and patients with an exemplar service – the vision of both founders.

I am pleased that Gresham House Ventures is investing in Panthera and we are delighted to have such a reputable and respected investment house as a shareholder

- Professor John Lyon, Chairman, Panthera Biopartners

Privacy Preference Center